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ABSTRACT 
Minimal residual disease prior to allogeneic hematopoietic cell transplantation has been 
associated with increased risk of relapse and death in patients with acute myeloid 
leukemia, but detection methodologies and results vary widely. We performed a 
systematic review and meta-analysis evaluating the prognostic role of minimal residual 
disease detected by polymerase chain reaction or multiparametric flow cytometry before 
transplant. We identified 19 articles published between January 2005 and June 2016 
and extracted hazard ratios for leukemia-free survival, overall survival, and cumulative 
incidences of relapse and non-relapse mortality. Pre-transplant minimal residual disease 
was associated with worse leukemia-free survival (HR=2.76 [1.90-4.00]), overall survival 
(HR=2.36 [1.73-3.22]), and cumulative incidence of relapse (HR=3.65 [2.53-5.27]), but 
not non-relapse mortality (HR=1.12 [0.81-1.55]). These associations held regardless of 
detection method, conditioning intensity, and patient age. Adverse cytogenetics was not 
an independent risk factor for death or relapse. There was more heterogeneity among 
studies using flow cytometry-based than WT1 polymerase chain reaction-based 
detection (I2=75.1% vs. <0.1% for leukemia-free survival, 67.8% vs. <0.1% for overall 
survival, and 22.1% vs. <0.1% for cumulative incidence of relapse). These results 
demonstrate a strong relationship between pre-transplant minimal residual disease and 
post-transplant relapse and survival. Outcome heterogeneity among studies using flow-
based methods may underscore site-specific methodological differences or differences 
in test performance and interpretation.   
 4 
INTRODUCTION 
Morphologic complete remission (CR), defined by the presence of <5% bone marrow 
blasts and recovery of peripheral blood counts, is the long-standing standard for 
response assessment in acute myeloid leukemia (AML).1-5 Based on estimates of normal 
marrow cellularity,6 however, this cutoff allows for the presence of up to 1010 leukemic 
blasts or more. It is therefore not surprising that relapse remains the major cause of 
treatment failure among patients who have achieved a morphologic CR.4, 5 Significant 
effort has gone into developing tools to identify minimal (or, perhaps more appropriately, 
measurable) residual disease (MRD), including multi-parametric flow cytometry (MFC) to 
enumerate myeloid cell populations with immunophenotypic abnormalities, polymerase 
chain reaction (PCR) to quantify leukemia-associated mutations or RNA transcript levels, 
and cytogenetic / fluorescence in situ hybridization to detect chromosome-level changes 
specific to the malignant clone. Among these modalities, MFC- and PCR-based 
approaches have the highest sensitivity and are increasingly employed in the clinic.7-12  
 
A large number of studies has demonstrated worse outcomes for patients who have 
MRD compared to similarly treated patients in whom no MRD can be detected. This 
relationship has been observed during/after induction and post-remission chemotherapy 
courses as well as before and after hematopoietic cell transplantation (HCT).7-12 The 
magnitude of the association between MRD status and risk of relapse varies widely 
between studies, however, as do the details of the detection methods. In addition to 
differences in the specifics of the MRD techniques across institutions, there are also 
differences in cut-points chosen to define MRD positivity, the patient material that is 
used to perform the MRD assay on (i.e., peripheral blood or bone marrow), and the 
timing as well as frequency with which MRD assessments are obtained. In this meta-
analysis, we focused on MRD assessed immediately before allogeneic HCT in patients 
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with AML other than acute promyelocytic leukemia (APL). Besides ascertaining the 
relationship between pre-HCT MRD and post-transplant outcomes, we also investigated 
whether, and to what degree, the prognostic role of MRD is influenced by the method of 
MRD detection.   
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METHODS 
We searched PubMed/MEDLINE and EMBASE (Supplemental Table 1) for English-
language articles published between January 2005 and June 2016 that reported on the 
association between pre-HCT MRD (by PCR and/or MFC) and post-HCT survival in 
patients with non-APL AML in morphologic CR. Two authors (S.A.B. and R.B.W.) 
independently reviewed search results. We excluded studies with <15 patients or <6 
months of follow-up. If needed, authors of included studies were contacted for additional 
information. Our search yielded 344 reports, which were screened according to 2009 
PRISMA Guidelines (Figure 1). For studies of interest, we collected data on the number 
of patients, median/range age, median follow-up time, percent of patients with adverse 
risk cytogenetics (using the classification criteria reported by study authors), percent of 
patients receiving myeloablative (MA) vs. reduced intensity conditioning (RIC), interval 
between MRD detection and HCT, and details of the MRD detection method. We 
assessed risk of bias using an instrument based on the Quality in Prognostic Studies 
(QUIPS)13 modified to reflect our judgment about potential biases (Supplemental Table 
2). Finally, we obtained data for leukemia-free survival (LFS), overall survival (OS), and 
cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) from the date of 
HCT. We used a hierarchical approach14 to compare outcomes of MRDpos and MRDneg 
subjects: (i) When available, we used observed hazard ratios (HRs) and confidence 
intervals (CIs); (ii) When Kaplan-Meier curves were provided, we used Enguage Digitizer 
version 4.1 (www.markummitchell.github.io/engauge-digiitizer/) to calculate HRs and CIs 
based on an established algorithm;15 (iii) For articles providing survival data at single 
time-points, we estimated HRs based on exponential decay.  
 
We performed a random-effects meta-analysis, with inter-study heterogeneity described 
using the I2 statistic16 (STATA version 14; Stata Corp, College Station, TX). Cut-points 
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between MRD positivity and negativity were based on criteria specified by the individual 
publications. In one,17 no cut-point was specified for Wilms Tumor 1 (WT1) transcript 
level. As other studies used cut points in the range of 50-70 copies/104 reference gene 
copies,18-20 and as no events were observed at WT1 levels <65, a cut-off of 70 was 
used. For another study18 that used a WT1 cutoff of 50, there were no relapses in the 
MRDneg group (n=25) by 6.6 years. As no HR could be calculated, this study was not 
incorporated into pooled CIR results. For two studies in which HRs were extracted from 
survival curves,21, 22 curves were portrayed for subgroups within MRDpos and MRDneg 
patients; here, a weighted average of the HR between groups by number of patients per 
group was used to obtain a final HR. For one study19 reporting results by MFC and by 
WT1 PCR, we used MFC results for overall analysis, as these data were more complete. 
 
Subgroup analyses involved stratification by MRD detection method, age, and 
conditioning intensity. We calculated the ratio of the percentage of patients with adverse 
cytogenetics in the MRDpos and MRDneg groups. If HRs for survival outcomes were 
higher in studies where this ratio was greater, it would indicate that adverse cytogenetics 
might be an independent negative prognostic factor.23 We used meta-regression to test 
this hypothesis. 
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RESULTS 
Included studies 
Our search yielded 19 unique publications with a total of 1,431 patients (Table 1).17-19, 21, 
22, 24-37
 Details of transplant and conditioning regimens are shown in Supplemental 
Table 3. The sole method of MRD detection was MFC in 9 studies22, 24, 26-29, 33, 36, 37 and 
WT1 PCR in 5,17, 18, 30-32 while one study reported results separately for MFC- and WT1 
PCR-based detection.19 Four studies used combination methods;21, 25, 34, 35 all of these 
included MFC, and 3 also included PCR-based detection. Among studies using MFC-
based detection, the cut point between MRD positivity and negativity was fairly uniform: 
11 of 14 used the limit of detection for the assay (around 0.1%), while 3 specified a cut-
off of 0.1%,26, 33, 36 which roughly corresponded to the limit of detection in these cases. In 
other words, heterogeneity in cut points was primarily determined by differences in 
performance characteristics and interpretation of the assay rather than cut points 
selected. Among studies that only used PCR-based methods, all assessed quantitative 
PCR for WT1, while one study31 utilized a panel of other genes in addition to WT1. Two 
studies, both using combination approaches for MRD detection, targeted PCR at AML-
specific mutations (e.g., Fms related tyrosine kinase 3 internal tandem duplication 
[FLT3/ITD])21 or fusions genes (e.g., RUNX1/RUNX1T1)25 present at diagnosis. Among 
studies quantifying WT1 transcript levels, most normalized against expression of ABL1; 
MRDpos cut-off levels varied between 50-70 copies WT1 per 104 copies of ABL1.17, 19, 32, 34  
 
Five studies were considered high risk of bias: MRD measurement technique was 
implicated in all cases, and study confounding was felt possible in 2 of these cases 
(Figure 2). For 11 studies, we were able to obtain HRs for all reported outcomes from 
the manuscript or personal communication; for the other 8 studies, HRs were 
extrapolated from Kaplan Meier curves or survival point estimates (n=4).18, 26, 34, 36 MRD 
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was measured within 60 days of HCT in all studies in which this information was 
reported, and within 30 days in all but one study.35 
 
Association between pre-HCT MRD status and post-HCT outcomes 
Overall, MRD positivity was associated with worse LFS (HR=2.76 [1.90-4.00], I2=70.0%), 
OS (HR=2.36 [1.73-3.22], I2=59.7%), and CIR (HR=3.65 [2.53-5.27], I2=37.9%) but not 
NRM (HR=1.12 [0.81-1.55], I2<0.1%). After removing studies with high risk of bias in any 
domain, MRD remained strongly associated with worse LFS (HR=3.24 [2.17-4.83], 
I2=64.5%), OS (HR=2.64 [1.87-3.72], I2=57.8%), and CIR (HR=4.06 [2.70-6.12], 
I2=48.0%) while, again, there was no statistically significant association with NRM 
(HR=1.18 [0.80-1.75] I2=0.9%).  
 
Effect of MRD detection method on post-HCT outcomes 
In subgroup analyses, being MRDpos was associated with increased risk of relapse and 
mortality regardless of the detection method (Table 2). For CIR, the HR for WT1 PCR-
based methods was statistically significantly larger than for MFC-based methods. Figure 
3 shows a forest plot for the 17 studies reporting on the primary outcome of LFS, while 
similar plots for OS, CIR, and NRM can be found in Supplemental Figures 1-3. Results 
for studies using MFC-based methods were more heterogeneous than those using WT1 
PCR or combination methods for LFS (I2=75.1% vs. <0.1% and 57.2%), OS (I2=67.8% 
vs. <0.1% and 12.5%), and CIR (I2=22.1% vs. <0.1% and 6.7%). After excluding studies 
with a high risk of bias in any domain, WT1 PCR-based studies and combination 
methods continued to have low heterogeneity for LFS, OS, and CIR (all I2<0.1%), 
whereas MFC-based studies showed persistent and considerable heterogeneity for LFS 
(I2=81.5%), OS (I2=73.8%), and CIR (I2=46.4%).  
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While all MFC-based studies analyzed bone marrow tissue, WT1 PCR-based studies 
were mixed between use of marrow and peripheral blood for analysis. Restriction to 
studies that reported data from peripheral blood18, 31, 32 yielded essentially identical 
results. Outcomes for MFC-based studies were similar regardless of whether residual 
disease was detected via gaiting for the original leukemia-associated immunophenotype 
or based on detecting a phenotype different from normal, although results for the latter 
were more heterogeneous (I2 89.7% vs. 32.5% for LFS, 88.3% vs. 0.0% for OS, and 
70.8% vs. 0.0% for CIR). There were no significant differences in outcomes between 
MFC-based studies by number of fluorochromes (<6 vs. ≥6) used.  
 
Effect of patient age on post-HCT outcomes 
On subgroup analysis of age 0-20,18, 25, 26, 30, 36 21-40,28, 31, 34 and >40,17, 19, 21, 22, 24, 27, 29, 32, 
33, 35
 we found no difference in the effect of MRD between groups. The same was true 
after exclusion of studies with high risk of bias. Among studies reporting on older 
patients, there was sufficient data to further stratify into ages 40-60 and >60 for the LFS 
endpoint; the HR for this outcome was similar in these subgroups (HR=2.67 [1.46-4.86], 
I2=81.1%; HR=3.02 [0.90-10.08], I2=52.3% respectively). When we restricted our 
analysis to studies using primarily MA conditioning, 2 were primarily pediatric (median 
age 0-20),25, 30 4 involved young adults (median age 20-40),27, 28, 31, 34 and 5 involved 
older adults (median age >40).19, 21, 24, 32, 35 The association between MRD and LFS was 
similar in all age groups among, though between-study heterogeneity was high (age 0-
20: HR=3.45 [0.39-30.86], I2=89.5%; age 20-40: HR=2.35 [1.10-5.02], I2=72%; age >40: 
HR=3.56 [1.79-7.05], I2=77.5%). 
 
Effect of conditioning intensity on post-HCT outcomes 
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Next, we considered whether differences in conditioning intensity might explain between-
study heterogeneity, particularly in light of conflicting results from Ustun et al27 showing 
in a large cohort (n=203) that MA conditioning could compensate for the increased 
hazard for relapse and mortality associated with being MRDpos, while Walter et al29 
showed no such effect in 241 patients. Among studies reporting LFS as an outcome, 14 
reported on the fraction of MRDpos and MRDneg patients who underwent MA versus RIC 
HCT. To test whether higher intensity transplant might reduce the negative impact of 
being MRDpos, we specifically analyzed studies in which >75% of MRDpos and MRDneg 
patients received MA HCT (n=12 for LFS endpoint) and compared results with studies 
where 0% of patients received MA HCT (n=3 for LFS endpoint). Results from Ustun at 
al27 were reported separately for MA and RIC patients within their publication, and for the 
purposes of this analysis, we treated these sets of results as two separate studies. As 
shown in Table 2 and as a forest plot in Supplemental Figure 4, there was no 
indication that MA conditioning was able to attenuate the negative effects associated 
with MRD positivity on LFS, OS, or CIR. In contrast, the HRs for MA studies were 
numerically higher than for the few RIC studies, although the large confidence intervals 
exclude a definitive conclusion as to whether conditioning intensity affects the 
association between MRD status and post-HCT outcomes. Exclusion of high-risk studies 
did not fundamentally change these results and conclusions. Not surprisingly, all studies 
using RIC conditioning involved older adults (the >40 age group as stratified above).  
 
Effect of cytogenetic risk on post-HCT outcomes 
Most studies reporting cytogenetics in MRDpos and MRDneg patients used Southwest 
Oncology Group17, 27, 28, 32, 33 or 2010 Medical Research Council criteria,21, 24, 29, 35 while 
one incorporated mutational profiling.34 The ratio of the proportion of adverse risk 
cytogenetics among MRDpos to MRDneg patients ranged from roughly equal to 7.5 times 
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higher in the MRDpos group. We used meta-regression to measure how HRs for LFS 
changed with variations in this risk ratio and found that differences in adverse risk 
cytogenetics between MRDpos and MRDneg groups did not account for a significant 
proportion of between-study variance (R2): R2 -9.15% (P=0.82) for all studies and -
14.83% (P=0.92) after excluding high-risk studies (Figure 4). Results were similar when 
the study with the highest ratio of 7.5 was excluded from this analysis (P=0.62). 
Similarly, adverse risk cytogenetics was not an independent prognostic factor for OS 
(P=0.11), CIR (P=0.85), or NRM (P=0.99).  
 
Testing for publication bias 
Funnel plot analyses for each survival outcome are shown in Figure 5 as a graph of log-
HR versus the variance in the log-HR. These plots did not suggest a publication bias, 
although they indicated that the publication of studies considered to have high risk of 
bias could bias overall study results towards the null for LFS, OS, and CIR.  
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DISCUSSION 
The findings from this meta-analysis support our major conclusion that the presence of 
MRD before allogeneic HCT identifies patients at higher risk of relapse and shorter 
survival relative to patients in whom no evidence of MRD is found. Although we were 
unable to incorporate results from one study with an incalculable HR for CIR (based on 
the lack of relapses among MRDneg patients), the findings from that report similarly 
support our conclusion. The association between MRD and post-HCT relapse and 
mortality is robust and is seen within all patient ages and regardless of which detection 
method is used. It is similarly found in those undergoing MA conditioning as well as RIC 
transplants without discernible difference in strength of association between these 
cohorts, suggesting that higher conditioning intensity may not be able to overcome the 
adverse impact of MRD. To the extent that we were able to control for differences in 
cytogenetic risk with meta-regression, the negative impact of being MRDpos superseded 
any potential adverse effects of having poor-risk cytogenetics. In comparison, our 
analysis indicates that pre-HCT MRD is not associated with a significantly increased risk 
of NRM, in line with the notion that the association between pre-HCT MRD and OS is 
entirely accounted for by disease relapse without significant contribution from HCT 
toxicity.  
 
Although our meta-analysis demonstrates a significant association between pre-HCT 
MRD status and post-HCT outcomes with both WT1 PCR- and MFC-based assays, we 
found a greater degree of heterogeneity in survival estimates in studies with MFC-based 
detection methods. This heterogeneity could not be accounted for by differences in 
patient age, conditioning intensity, or cytogenetic risk. In addition, the cut-points between 
MRD positivity and negativity were primarily determined by the limits of detection of each 
particular assay, indicating that chosen cut-points are unlikely to account for 
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heterogeneity. We were, however, able to show that at least some of this heterogeneity 
may be accounted for by study-specific differences in approach to MFC, with studies 
detecting residual disease based on initial leukemia-associated immunophenotypes 
having more uniform results than those using a “different from normal” approach. Other 
possible causes of heterogeneity might include site-specific differences in MFC 
methodology, including differences in antigens and fluorochromes used, methods for cell 
lysis, number of events collected, or specifics of the aspirate used for analysis, with 
increasing risk of hemodilution with each pull. If such speculation is correct, efforts 
towards standardization/harmonization of MRD methods – as pioneered in acute 
lymphoblastic leukemia38 and currently underway for AML – might ultimately lead to less 
heterogeneous data with MFC-based MRD assays. In contrast, despite some 
heterogeneity in PCR targets and cut-points, PCR methodology may be relatively more 
standardized, accounting for more uniform results. As an illustration, the risk estimates 
for being MRDpos by PCR-quantified WT1 transcript levels are very similar across several 
studies, indicating that this method yields highly reproducible results for pre-HCT risk 
stratification. Even in the smallest studies,17,19 in which there was no statistically 
significant relationship between MRD and LFS, observed HRs were consistent with the 
other, larger studies. One might wonder whether using more than one method to detect 
MRD might lead to more sensitive detection and stronger associations with relapse and 
survival, indicated by higher HRs. We found that studies using combination methods of 
MRD detection did not show stronger associations with survival outcomes over studies 
using either MFC- or WT1 PCR-based methods. That said, all four of these 
‘combinations’ involved MFC-based detection, and the heterogeneity within the 
combination group may simply underscore the heterogeneity in MFC-based studies as a 
whole. Alternatively, MFC and WT1 PCR are both potentially highly sensitive tests, and 
using multiple modalities may not add much additional sensitivity in detection, or 
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increases in assay sensitivity beyond current limits may not lead to appreciably stronger 
associations with survival outcomes. 
 
Although our studies highlight the importance of pre-HCT MRD, we were unable to 
account for inter-study differences in the selection of patients for HCT, which may impact 
post-HCT results. It is conceivable that different strategies in allocating patients to 
different post-remission treatment strategies could affect our study results. Given the 
nature of our analysis, we were only able to test the effects of select covariates and only 
in aggregate fashion. Similarly, we were not able to control for the considerable 
heterogeneity in transplant conditioning regimens, donor sources, graft characteristics, 
and immunosuppression, all of which could potentially influence relapse and death. 
Absent individual patient data, we were not able to assess whether higher levels of MRD 
were associated with higher risk of relapse. Regardless of these limitations, our results 
demonstrate a strong relationship between pre-HCT MRD status and post-HCT relapse 
and survival but not NRM. Further studies are needed to determine how pre-HCT MRD 
status should guide therapeutic decisions, either through treatment intensification for 
MRDpos patients or possibly de-intensification for patients who are found to be MRDneg by 
a reliable method. 
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Table 1. Characteristics of included studies 
 
Study MRD method MRD 
source 
Cutoff for 
MRDpos 
MRDneg 
(n) 
MRDpos 
(n) 
Age, median 
(range) 
% MA 
Bleyzac et 
al26 
MFC (LAIP) BM 0.1%  18 14 9 (0-19) NR 
Ustun et al27 MFC (DFN, 4-
color) 
BM Limit of 
detection (0.1%) 
178 25 47 (0-74) 39% MRDneg 
60% MRDpos 
Zheng et al25 MFC (LAIP, 4-
color) 
or PCR (fusion 
genes, multiple) 
BM MFC: 0.01% 
PCR: limit of 
detection 
40 32 MRDneg 16 (3-28) 
MRDpos 19 (6-36) 
100% 
Araki et al24 MFC (DFN, 10-
color) 
BM Limit of 
detection 
(0.1%) 
235 76 MRDneg 47 (19-71) 
MRDpos 51 (18-72) 
100% 
Goswami et 
al31 
PCR (WT1, 
multi-gene) 
PB Different for 
each gene 
38 10 MRDneg 34 (12-59) 
MRDpos 34 (16-53) 
89% MRDneg 
100% MRDpos 
Rossi et al19 MFC (LAIP, 6-
color) 
PCR (WT1) 
BM MFC: 0.1% 
WT1: 64 / 104 
copies ABL  
22 (MFC) 
19 (PCR) 
8 (MFC) 
10 
(PCR) 
44 (18-64) 100% 
Tian et al28 MFC (LAIP, 4-
color) 
BM Limit of 
detection 
21 32 MRDneg 31 (15-55) 
MRDpos 32 (16-58) 
NR 
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Walter et al29 MFC (DFN, 10-
color) 
BM Limit of 
detection 
(0.1%) 
65 21 MRDneg 62 (20-75) 
MRDpos 63 (33-74) 
0% 
Woehlecke 
et al30 
PCR (WT1) PB or 
BM 
5 × 10-3 
normalized to  
β2M expression  
17 23 MRDneg 4 (1-21) 
MRDpos 13 (2-18) 
100% 
Anthias et 
al22 
MFC (LAIP, 3-
color) 
BM Limit of 
detection (0.4%) 
53 35 MRDneg 44 (18-70) 
MRDpos 52 (21-70) 
40% MRDneg 
60% MRDpos 
Bastos-
Oriero et al33  
MFC (LAIP, 4-
color) 
BM 0.1% 18 11 MRDneg 41 (19-62) 
MRDpos 50 (19-63) 
100% MRDneg 
72% MRDpos 
Kanakry et 
al21 
MFC (LAIP), 
PCR (FLT3, 
NPM1), and/or 
cytogenetics / 
FISH 
BM MFC: limit of 
detection 
PCR: limit of 
detection 
76 25 51 (20-66) 100% 
Wang et al34 MFC (LAIP) 
and PCR (WT1) 
BM MFC: limit of 
detection 
WT1: 60 / 104 
copies ABL 
110 20 26 (3-54) 100% 
Grubovikj et 
al35 
MFC (DFN) 
or cytogenetics 
/ FISH 
 Limit of 
detection 
40 19 MRDneg 43 (20-65) 
MRDpos 50 (28-65) 
90% MRDneg 
84% MRDpos 
 22
Leung et al36 MFC (LAIP, 4-
color) 
BM 0.1% 27 9 (Pediatric) 100% 
Valkova et 
al32 
PCR (WT1) PB 50 / 104 copies 
ABL1 
29 13 MRDneg 43 (20-63) 
MRDpos 51 (36-63) 
79% MRDneg 
85% MRDpos 
Candoni et 
al17 
PCR (WT1) BM 70 / 104 copies 
ABL1 
5 13 MRDneg 61 (39-66) 
MRDpos 61 (36-68) 
0% 
Jacobsohn et 
al18 
PCR (WT1) PB 0.5 (normalized 
to WT1 level in 
control cells)  
25 11 10 (3-22) 100% 
Laane et al37 MFC (LAIP, 3-
color) 
BM Limit of 
detection 
12 5 (Adult) 100% 
Abbreviations: PB, peripheral blood; BM, bone marrow; NR, not reported; MFC, multiparametric flow cytometry; LAIP, leukemia-
associated immunophenotype; MA, myeloablative; DFN, different from normal; WT1, Wilms tumor 1; β2M, β2-microglobulin; FISH, 
fluorescence in situ hybridization; FLT3, Fms related tyrosine kinase 3 
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Table 2: Pooled HRs [95% CI] and inter-study heterogeneity for all studies (above) and excluding high risk of bias 
(below). Only fields pooled from ≥2 studies are reported; otherwise, fields are left blank. Colored boxes indicate 
degree of heterogeneity as defined by the I2 statistic: 0-24.9% = low (), 25-75% = moderate ( ), 75.1-100% = high 
( ).39 Cells are filled only if two or more studies contribute to the analysis.  
 
All Studies 
Subset OS LFS CIR NRM 
Method 
 
MFC 1.98 [1.26-3.10]   2.41 [1.36-4.29]   2.81 [1.94-4.08]  1.11 [0.63-1.95]  
PCR 5.25 [3.08-8.95]  5.80 [3.57-9.42]  9.53 [4.48-20.29]  1.51 [0.57-4.00]  
Combination 1.86 [1.25-2.77]  1.79 [1.06-3.01]   3.73 [1.94-7.18]  1.15 [0.57-2.33]  
Median age 
 
0-20 3.12 [1.29-7.57]   3.33 [0.95-11.6]   3.57 [0.67-18.91]   1.13 [0.52-2.4]  
21-40 2.60 [1.36-4.99]   3.02 [1.27-7.16]   5.13 [2.37-9.64]  -- 
>40 2.25 [1.47-3.47]   2.69 [1.64-4.42]   3.33 [2.18-5.11]   1.23 [0.77-1.97]  
Conditioning 
 
>75% MA 2.64 [1.77-3.93]   2.86 [1.80-4.55]   4.21 [2.70-6.58]   1.39 [0.94-2.07]  
0% MA 2.05 [0.78-5.39]   2.09 [1.33-3.29]  3.23 [1.88-5.53]  0.58 [0.22-1.52]  
 
Excluding Studies with High Risk of Bias 
Subset OS LFS CIR NRM 
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Method 
 
MFC 2.19 [1.29-3.72]   2.77 [1.39-5.50]   2.90 [1.81-4.64]   1.11 [0.63-1.95]  
PCR 4.60 [2.60-8.14]  5.14 [3.04-8.72]  9.53 [4.48-20.29]  1.28 [0.41-4.03]   
Combination 2.57 [1.52-4.33]  2.81 [1.70-4.66]  4.53 [2.30-8.92]   
Median age 
 
0-20 4.41 [1.65-11.8]   5.89 [1.90-18.2]   -- 1.16 [0.18-7.58]   
21-40 3.29 [1.39-7.79]   4.13 [1.19-14.3]   5.66 [2.80-11.4]  -- 
>40 2.46 [1.56-3.86]   3.06 [1.85-5.05]   3.33 [2.18-5.11]   1.23 [0.77-1.97]  
Conditioning 
 
>75% MA 3.39 [2.20-5.22]   4.09 [2.53-6.62]   4.72 [2.97-7.50]   1.42 [0.90-2.25]  
0% MA 2.05 [0.78-5.39]   2.09 [1.33-3.29]  3.23 [1.88-5.53]  0.58 [0.22-1.52]  
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Figure Legends: 
 
Figure 1: PRISMA flow diagram for study selection 
 
Figure 2: Risk of bias assessment illustrating review authors’ judgments about each risk 
of bias item for each included study.  
 
Figure 3: Forest plot showing hazard ratio (effect size, ES) for leukemia-free survival 
with pooling of results for each minimal residual disease detection method. Columns 
indicate study size (N) and whether each study carries a high risk of bias (Bias Risk). 
Within groups, studies are listed by year of publication. 
 
Figure 4: Meta-regression analysis showing the effect of the ratio of percent of MRDpos 
patients with adverse cytogenetics to percent of MRDneg patients with adverse 
cytogenetics on hazard for leukemia-free survival. A flat line indicates no relationship, 
and this is shown for all studies (a) and after excluding studies with high risk of bias (b).  
 
Figure 5: Funnel plot analysis for survival outcomes. Shown are (a) leukemia-free 
survival, (b) overall survival, (c) cumulative incidence of relapse, (d) non-relapse 
mortality. 
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SUPPLEMENTAL MATERIALS 
 
Supplemental Table 1: Search strategies for PubMed and EMBASE, with additional 
restrictions on year of publication starting January 1st, 2005 and English-language 
publications. In EMBASE, only published articles were included. 
	
PubMed strategy EMBASE strategy 
(“acute myeloid leukemia” OR “acute 
myelogenous leukemia” OR “acute myeloid 
leukaemia” OR “acute myelogenous 
leukaemia” OR "acute myeloblastic 
leukemia" OR "actue myeloblastic 
leukaemia" OR AML OR "leukemia, 
myeloid, acute"[MeSH])  
AND  
(transplant OR transplantation OR 
transplanted OR transplants OR 
transplantations OR HCT OR HSCT OR 
allogeneic OR BMT OR “stem cell 
transplantation”[MeSH])  
AND  
(“residual disease” OR MRD OR "residual 
leukemia" OR "stringent complete 
remission" OR "stringent CR" OR 
“neoplasm, residual”[MeSH]) 
('acute myeloblastic leukemia'/exp OR 
"acute myeloid leukemia" OR "acute 
myeloid leukaemia" OR "acute 
myelogenous leukemia" OR "acute 
myelogenous leukaemia" OR "acute 
myeloblastic leukemia" OR "acute 
myeloblastic leukaemia" OR AML)  
AND  
('minimal residual disease'/exp OR 
"residual cancer" OR "residual disease" 
OR "residual leukemia" OR "residual 
leukaemia" OR mrd OR “stringent 
complete remission” OR “stringent CR”) 
AND  
('stem cell transplantation'/exp OR HSCT 
OR HCT OR transplant OR transplants OR 
transplanted OR transplantation OR 
allogeneic OR BMT) 
	
	 	
Supplemental Table 2: Risk of bias assessment tool used to assign risk of bias  
	
Bias Domains Study Characteristics Risk of Bias 
Prognostic Factor 
Measurement 
Pre-HCT measurement of MRD is 
appropriate  
(a) MRD detection method must be 
clearly described, valid, and reliable.  
(b) Continuous variables are 
reported or pre-specified cut points 
are used. 
(c) MRD is measured close enough 
to the start of transplant to capture a 
true “pre-transplant” state 
High risk: MRD detection methods not described or 
likely to be inaccurate based on the following criteria:  
• MRD measured >60 days before transplant 
• For MFC, methodology is suspect based on 
(1) reported sensitivity not consistent with 
number of cells collected and reagent panels 
used,  (2) details such as cells/tube and 
antibody panels neither provided nor 
referenced, (3) center has not had prior 
publications with referenced protocols if not 
using their own protocol, or (4) <105 cells/tube 
used. 
• For PCR, methodology is suspect based on 
(1) >24 hours between specimen collection 
and RNA extraction, (2) lack of negative and 
standard controls, and (3) failure to perform 
the assay with >1 replicate. 
Moderate risk: cut points between MRD+ and MRD- 
are chosen based on exploratory analysis without a 
validation cohort and/or time between measurement 
and transplant not reported. Further, there is 
insufficient information to assess bias in MFC or PCR 
methodology. 
Low risk: MRD measurement is valid, with a pre-
specified cut-point between MRD+ and MRD-, and 
MRD is measured within 60 days of transplant. 
Study Confounding Important potential confounding 
factors are described 
(a) Confounders are measured 
across all participants and are 
reported separately for MRD+ and 
MRD- patients; key covariates are 
age, cytogenetics, and conditioning 
intensity. 
(b) Inclusion of patients not in CR 
may bias the MRD+ group toward 
worse outcomes. 
High risk: no key covariates are reported for MRD+ 
and MRD- patients. 
Moderate risk: only some key covariates are 
reported for MRD+ and MRD- patients. 
Low risk: all key covariates are reported for MRD+ 
and MRD- patients. 
Statistical Analysis 
and Reporting 
The statistical analysis is 
appropriate, and all primary 
outcomes are reported 
(a) Statistical methods are 
described, and there is no selective 
reporting of results 
(b) Hazard ratios for outcomes 
should be accurate  
High risk: the reported results are likely to be biased 
related to selective reporting of data (not all outcomes 
described in methods reported in results). 
Moderate risk: hazard ratios and confidence intervals 
must be extrapolated from survival curves or point-
estimates. 
Low risk: hazard ratios with confidence intervals are 
reported or obtained from individual patient data. 
	
Supplementary Table 3: Details of conditioning regimens, stem cell sources, and 
GVHD prophylaxis for each study 
 
Study Conditioning Stem Cell Source GVHD Prophylaxis 
Bleyzac et 
al26 
MA: TBI or Bu-based  43% MRD 
14% MURD  
43% MMURD 
CsA + 7.5 mg/kg rabbit 
ATG for URD + 
corticosteroids for CBT 
Ustun et al27 MA: Cy/TBI [1320 cGy] or Flu/Bu + 
melphalan or Bu/Cy.  
or 
RIC: Cy/Flu/TBI [200 cGy] or Flu/Bu ± ATG. 
MRD or UCB CsA + MMF or sirolimus 
+ MMF for UCB or RIC. 
CsA + MTX for others. 
Zheng et 
al25 
MA: Bu [12.8 mg/kg] / Cy [120 mg/kg] + 
HDAC  
or  
MA: Cy [120 mg/kg] / TBI [1200 cGy] + 
HDAC 
UCB (mostly single unit) CsA + MMF  
Araki et al24 MA: various – Bu/Cy ± low-dose TBI, 
Bu/Flu, Bu/etoposide, Bu/clofarabine, high-
dose TBI ± Cy or Flu, high-dose 
TBI/thiotepa/Flu, treosulfan/Flu ± low-dose 
TBI, Flu/low-dose TBI + radiolabeled 
antibody ± Cy 
40% MRD 
60% unrelated donor 
 
CI + MTX (73%), CI + 
MMF (11%), Cy ± CI ± 
MMF (13%), other (3%) 
Goswami et 
al31 
MA (92%): Cy [120 mg/kg] / TBI or Flu [125 
mg/m2] / Cy / TBI [1200-1360 cGy except 
600 cGy for older adults in some cases] 
or 
RIC: Flu-based [125 mg/m2] 
Mostly MRD, T-cell 
depleted 
CsA 
Rossi et al19 MA: Cy [120 mg/kg] / TBI [1200 cGy]  
or 
MA: Bu [9.6 mg/kg] + tepadine [10 mg/kg] + 
Flu [150 mg/m2] 
54% MRD, 33% MURD, 
13% MMRD 
CI + MTX + ATG. Cy 
added for MMRD 
Tian et al28 MA: Bu [9.6 mg/kg] / Cy [3.6 g/m2] 
or 
MA: TBI [750 cGy] / Cy [3.6 g/m2] 
or 
MA: Bu or TBI/Cy + rabbit ATG  
53% MRD 
21% MURD 
26% MMRD 
Some had planned DLI day 
26 provided no GVHD 
CSA + MMF + MTX 
Walter et 
al29 
RIC: low-dose TBI ± Flu or clofarabine 44% MRD 
66% unrelated donor 
CI + MMF ± rapamycin 
Woehlecke 
et al30 
MA (subset): mostly TBI or Bu-based 30% MRD 
46% MURD 
24% MMURD 
Not listed 
Anthias et 
al22 
MA: Cy / TBI ± alemtuzumab (for URD) 
or 
RIC Flu + melphalan + alemtuzumab 
34% MRD 
57% unrelated donor 
9% UCB 
Not listed 
Bastos-
Oriero et al33 
Not listed (86% MA) 46% MRD 
32% MURD 
15% UCB 
7% MMRD 
Not listed 
Kanakry et 
al21 
MA: Bu [targeted] /Cy [100 mg/kg] or Bu 
[targeted] / Flu [160 mg/m2] 
57% MRD 
43% MURD 
Post-transplant Cy [50 
mg/kg days +3 and +4] 
Wang et al34 MA: cytarabine [8 g/m2] + Bu [9.6 or 12 
mg/kg] + Cy [3.6 g/m2] + semustine [250 
mg/m2] ± ATG 
100% MMRD CSA + MMF + MTX 
Grubovikj et 
al35 
88% MA 
46% TBI-based 
57.6% related 
78% matched 
Not listed 
Leung et al36 MA: TBI/Cy (for matched) 
or 
MA: TBI-based or Flu + melphalan-based 
regimens (for haploidentical) 
Not listed 
T-cell depletion used for 
haploidentical 
CsA + MTX or MMF 
Valkova et 
al32 
MA: TBI or Bu-based 
or 
RIC: Flu + Bu or melphalan or TBI [200 cGy] 
38% MRD 
38% MURD 
24% MMURD 
CI ± MMF 
Candoni et 
al17 
RIC: Flu/Bu, Cy/thiotepa, treosulfan/Flu 56% MRD 
38% URD 
6% UCB 
Not listed 
Jacobsohn 
et al18 
MA: TBI [1200 cGy] / Cy [120 mg/kg] + 
etoposide [1 g/m2] 
or  
MA: Bu [12.8 mg/kg] / Cy [240 mg/kg] 
or 
RIC: Flu [180 mg/m2] / Bu [targeted] + rabbit 
ATG 
36% MRD 
17% MURD 
47% UCB  
Not listed 
Laane et al37 Not listed (100% MA) Not listed Not listed 
Abbreviations: ATG, anti-thymocyte globulin; Bu, busulfan; CBT, cord blood transplant; 
CI, calcineurin inhibitor; CsA, cyclosporine A; Cy, cyclophosphamide; Flu, fludarabine; 
GVHD, graft-versus-host disease; HDAC, high-dose cytarabine; MA, myeloablative; 
MMF, micophenolate mofetil; MMRD, mismatched related donor; MMURD, mismatched 
unrelated donor; MRD, matched related donor; MTX, methotrexate; MURD, matched 
unrelated donor; RIC, reduced intensity conditioning; TBI, total body irradiation	  
Supplemental Figure 1: Forest plot showing hazard ratio (effect size, ES) for overall 
survival with pooling of results for each MRD detection method. Columns indicate study 
size (N) and whether each study carries a high risk of bias (Bias Risk). Within each 
section, studies are listed by year of publication. 
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Supplemental Figure 2: Forest plot showing hazard ratio (effect size, ES) for 
cumulative incidence of relapse with pooling of results for each MRD detection method. 
Columns indicate study size (N) and whether each study carries a high risk of bias (Bias 
Risk). Within each section, studies are listed by year of publication. 
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Supplemental Figure 3: Forest plot showing hazard ratio (effect size, ES) for non-
relapse mortality with pooling of results for each MRD detection method. Columns 
indicate study size (N) and whether each study carries a high risk of bias (Bias Risk). 
Within each section, studies are listed by year of publication. 
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Supplemental Figure 4: Forest plot showing hazard ratio (effect size, ES) for leukemia-
free survival with pooling of results for studies using predominantly myeloablative and 
exclusively non-myeloablative conditioning strategies. Columns indicate year of 
publication (Year), study size (N), and method of MRD detection (Method).  
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